Stay updated on Pembrolizumab vs. Liver-Directed Therapy in NET Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab vs. Liver-Directed Therapy in NET Clinical Trial page.

Latest updates to the Pembrolizumab vs. Liver-Directed Therapy in NET Clinical Trial page
- Check4 days agoChange DetectedThe footer revision number changes from v3.7.1 to v3.7.2; the page continues to show a 403 Forbidden error.SummaryDifference0.2%

- Check11 days agoChange DetectedThe footer revision identifier changes from v3.7.0 to v3.7.1; the page still displays a 403 Forbidden error.SummaryDifference0.2%

- Check18 days agoNo Change Detected
- Check32 days agoChange DetectedThe page now renders a 403 Forbidden error with accompanying header text, and the visible study content appears unavailable while the site header/footer remain; this indicates the study record is currently inaccessible.SummaryDifference21%

- Check54 days agoChange DetectedResults were posted on 2026-08-28 with the study marked as Completed. The update adds result sections for ORR, DOR, PFS, and irPFS, and provides links to the Study Protocol and Statistical Analysis Plan, along with the Results First Posted timeline.SummaryDifference2%

- Check68 days agoChange DetectedThe page now shows the full Study Details for NCT03457948, including enrollment and study dates, sponsor and collaborators, and locations. It also adds detailed Study Record Dates metadata (First Submitted, First Posted, Last Update, Study Record Updates) to document the record history.SummaryDifference60%

- Check75 days agoChange DetectedThe page's revision metadata was updated from v3.6.4 to v3.6.5, indicating an incremental version update.SummaryDifference0.1%

Stay in the know with updates to Pembrolizumab vs. Liver-Directed Therapy in NET Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab vs. Liver-Directed Therapy in NET Clinical Trial page.